The invention relates to pharmaceutical preparations having controlled release of active compound and to processes for their preparation, in particular for poorly soluble active compounds having problematic bioavailability.
The invention relates to pharmaceutical preparations, containing a specific crystal modification (subsequently called "modification II") of isopropyl-(2-methoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (nimodipine) and to a process for its preparatio
